Home › Post-COVID Conditions (Long COVID) › NCT05164744
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Emergency room presentation and/or hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea/vomiting, myalgias, fever, syncope/presyncope. Exclusion criteria: * Contraindication to CMR (i.e. non-compatible pacemaker/defibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \<30 ml/min/1.73m2). * Inability to provide informed consent (e.g. cognitive impairment). * Unrelated condition (e.g. neoplasm) with life expectancy \<12 months prohibiting follow-up. * Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \< 30 ml/min/1.73m2) will undergo non-contrast MRI but will not be excluded from this study. * Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.
About the study
The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.
What is being tested
- Cardiac MRI (diagnostic test)
- Echocardiogram (diagnostic test)
- 6-minute walk test (diagnostic test)
- Questionnaire (diagnostic test)
Sponsor: Weill Medical College of Cornell University · Participants: 510 · Started: Jul 1, 2021
Contact the study team
- Elizabeth Manowitz, BS · Phone: 2127462627
- Mahniz Reza, BA · Phone: 2127462627
Official record on ClinicalTrials.gov — NCT05164744
Locations in the U.S.
| New York | New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn New York Presbyterian Queens, New York Weill Cornell Medicine/New-York Presbyterian Hospital, New York |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.